TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06522100
Drug: Perfusion of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take perfusion of placebo (G5%: 100ml over 30 minutes per day) for 3 days.
Study: NCT04065672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a 4-week screening period, patients received placebo subcutaneously every other day. After the initiation of the therapy, patients could continue with concurrent medication but were prohibited from changing or adding immunosuppression therapy during the course of the study with a 12-week observational followed up.
Study: NCT05106400
Drug: ZTlido (Lidocaine Topical System) 1.8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ZTlido (Lidocaine Topical System) 1.8% is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours
Study: NCT04814004
Drug: hCD19.IL15.CAR-iNKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal hCD19.IL15.CAR-iNKT cells by a single infusion intravenously will be given in escalating doses.
Study: NCT05950815
Drug: CD73 Antigen
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will be administered with PM1015 via intravenously (IV) Q2W pemetrexed until progression or accepted other treatment.
Study: NCT05805917
Drug: Connettivina 0.2% Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Connettivina 0.2% Cream will be applied twice daily, to cover the entire cutaneous surface interested by burns, followed by a gentle massage to spread the product evenly of all the affected skin.
Study: NCT06437041
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
Study: NCT03594630
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive chemotherapy
Study: NCT05505955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects took Placebo in Part 1 and Part 2.
Study: NCT04539795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT05248919
Drug: Epclusa (nucleotide HCV NS5B polymerase inhibitors).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400mg/day) and Velpatasvir(100mg/day) for 12 weeks or 24 weeks
Study: NCT05425472
Drug: HR070803
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR070803
Study: NCT05461131
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antibiotic
Study: NCT05744674
Drug: HR18034
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR18034 228mg/342mg/456mg
Study: NCT03896516
Drug: GLWL-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLWL-01 is a ghrelin O-acyltransferase (GOAT) inhibitor. Participants receive GLWL-01 orally twice daily.
Study: NCT05326490
Drug: PB-201 matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively
Study: NCT05235269
Drug: I124-AT01 only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of I124-AT01 on Day 1 and again at Week 6 followed by a full body Positron Emission Tomography/Computed Tomography (PET/CT) scan.
Study: NCT05830396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will either receive ambroxol or placebo. ambroxol will be given intially in a dosage of 600mg/day. After 1 week, this will be increased to 1200mg/day. After 2 weeks the maximum dosage of 1800mg/day will be given. In total, ambroxol will be administered for 48 weeks. This is followed by a 12 week washout period, after wich the final outcomes will be measured (week 60).
Study: NCT05360953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients enrolled establish their individually tolerable dose by dose Titration. Dosage up to a maximum of 5 capsules. Using capsules of placebo.
Study: NCT05183360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06297642
Drug: TQB2928 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD47 monoclonal antibody
Study: NCT06555549
Drug: DEH113
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT06555549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT05385770
Drug: AZM X mg + AML Y mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, single dose, QD, oral administration
Study: NCT05385770
Drug: AZM X mg + AML Y' mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, single dose, QD, oral administration
Study: NCT05385770
Drug: AZM X' mg + AML Y mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, single dose, QD, oral administration
Study: NCT05385770
Drug: AZM X' mg + AML Y' mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, single dose, QD, oral administration
Study: NCT05385770
Drug: AZM X mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, single dose, QD, oral administration
Study: NCT05385770
Drug: AZM X' mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, single dose, QD, oral administration
Study: NCT05385770
Drug: AML Y mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, single dose, QD, oral administration
Study: NCT05385770
Drug: AML Y' mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, single dose, QD, oral administration
Study: NCT06182085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT06654934
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 8 weeks, 5 mg/day for 4 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 2485 mg).
Study: NCT06654934
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 14 weeks, 5 mg/day for 24 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 3605 mg).
Study: NCT06594432
Drug: R-CHOP+Z+MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and MCD, BN2, and N1 subtypes will receive 5 cycles of R-CHOP combined with MTX + Zanubrutinib, followed by 1 cycle of R-MTX-Zanubrutinib.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles.
Study: NCT06594432
Drug: R-CHOP+MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: After receiving 1 cycle of pre-treatment with the R-CHOP regimen, patients with CSF-ctDNA (+) and EZB, A53, and other gene subtypes will receive 5 cycles of R-CHOP combined with MTX, followed by 1 cycle of R-MTX.~After completing the above induction therapy, Patients with negative CSF-ctDNA results will continue with one more cycle of Rituximab. For patients with positive CSF-ctDNA results, the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.~Each combined regimen consists of a 21-day treatment cycle, and efficacy will be evaluated every three treatment cycles.
Study: NCT04806464
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.
Study: NCT06172309
Drug: NTQ1062
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet(s) PO
Study: NCT06169059
Drug: JLP-2004
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of JLP-2004(COX-2 inhibitor)
Study: NCT04808661
Drug: Optimal medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (strictly control of their blood pressure and heart rate)
Study: NCT05684211
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinotecan hydrochloride，180mg/m2，intravenous titration，Q2W； 5 -Fluorouracil，400 mg/ m2, intravenous push, then 1200 mg/ m2 /day x 2 days, intravenous titration,Q2W; Calcium folinate,400mg/m2,intravenous titration，Q2W
Study: NCT00279487
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00751517
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00751517
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06255431
Drug: Ezerra cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: The research subjects were divided into 2 groups: group A (intervention cream on the right side of the face and control cream on the left side of the face) and group B (intervention cream on the left side of the face and control cream on the right side of the face).~The test material consists of a cream containing a mixture of spent grain wax extract, shea butter, and argan oil, along with a vehicle cream. Vehicle cream was prepared by the Pharmacy Department of Faculty of Medicine Universitas Indonesia and has similar consistency, color, and scent as the intervention cream.The creams are applied to the face twice daily (0,5 FTU), immediately after washing, in equal amounts on each side of the face. The creams are applied for 7 days, and participants are instructed to use appropriate sunscreen.
Study: NCT00002002
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05489016
Drug: Yuekang Huoxin Pills (concentrated pills)simulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huoxin Pill (concentrated pill) simulant, a placebo-like simulation have no therapeutic effect. The shape, packaging and taste are the same as Huoxin Pill (concentrated pill), produced by Guangzhou yuekang biopharmaceuticals co., ltd.
Study: NCT05877508
Drug: AER002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of AER002
Study: NCT05438303
Drug: AZD9833
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9833 tablets will be administered orally once daily on Days 1 - Day 5 (Treatment Period 2) and Day 1 (Treatment Period 3) for participants recruited to Arms A and C and Day 1 for those in Arm B
Study: NCT05438303
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A Celecoxib capsule will be administered once on Day 1 of Treatment Periods 1 and 3
Study: NCT06273215
Drug: The combinations of 10 µg midazolam, 375 µg dabigatran etexilate, 10 µg pitavastatin, 50 µg rosuvastatin, and 100 µg atorvastatin were administered to diabetic patients on an empty stomach.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam, dabigatran etexilate, pitavastatin, rosuvastatin and atorvastatin were provided by the Department of Pharmacy, Peking University Third Hospital, and were dissolved and mixed with normal saline respectively, and the mixing process needed to be fully stirred. Then, according to the concentration of the drug mixed solution, the corresponding volume of mixed solution was given to achieve the dosage of 10 μg midazolam, 375 μg dabigatran etexilate,10 μg pitavastatin, 50 μg rosuvastatin and 100 μg atorvastatin. In order to avoid the food effect, the test drugs were administered on an empty stomach on the administration day in this experiment.
Study: NCT06649110
Drug: LTP
Normalized name: Saltpeter
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTP001
Study: NCT06649110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00040989
Drug: BAY 56-3722
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06329076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo tablets
Study: NCT00002999
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05357651
Drug: LB1410
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1 and anti-TIM-3 bispecific antibody
Study: NCT05024032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03550352
Drug: TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will start by taking 1 capsule twice daily for 1 week (5 mg THC/5 mg CBD) and increase the number of capsules as tolerated to a maximum of 6 capsules taken throughout the day by weeks 5-12 (15 mg THC/15 mg CBD total per day).
Study: NCT03550352
Drug: TN-C200M2 oral capsules (CBD 200 mg)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will start by taking 1 capsule once daily for 1 week (200 mg CBD) and increase the number of capsules as tolerated to a maximum of 4 capsules taken throughout the day by weeks 5-12 (800 mg CBD total).
Study: NCT05494164
Drug: standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal corticosteroids in addition to nasal irrigation with sea water; for patients with allergy the standard treatment is oral antihistamines with or without oral corticosteroids.
Study: NCT04801017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride injection
Study: NCT04840823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06091826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections
Study: NCT05825573
Drug: Vitamin K antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: VKA study medications (Warfarin, Fluindione and Acenocoumarol) will be prescribed and supplied in the usual setting of patient care with respect of the international guidelines and recommended dose protocols and will not be specifically supplied for the trial. Anticoagulant treatment will be prescribed for 6 months. The recommended INR target will be \[2-3\] and \[2-2.5\] for patients treated with concomitant antiplatelet therapy. Biological monitoring will be performed at discretion of physicians as usual care.
Study: NCT05825573
Drug: Direct oral anticoagulant
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOA study medications (Apixaban, Rivaroxaban and Dabigatran) will be prescribed and supplied in the usual setting of patient care and will not be specifically supplied for the trial. The usual doses of DOA will be prescribed: dabigatran 150mg twice a day, apixaban 5mg twice a day and rivaroxaban 20mg once a day. The adjusted doses (dabigatran 110mg twice a day, apixaban 2.5mg twice a day and rivaroxaban 15mg once a day) will be prescribed according to clinical practice treatment guidelines.
Study: NCT06067217
Drug: Progynova 1 mg oral tablet
Normalized name: Progynova 1 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compare between tranexamic acid and progynova to stop abnormal uterine bleeding in DMPA users
Study: NCT05585606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume Matched Placebo
Study: NCT05585606
Drug: scp776 (1.9 mg/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~- 1.9 mg/kg
Study: NCT05585606
Drug: scp776 (3.8 mg/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1 dose regimen:~Intravenous (IV) slow injection(s) over 2 minutes~- 3.8 mg/kg
Study: NCT05478837
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05234697
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil was used for maintenance of anesthesia.
Study: NCT05330286
Drug: LMI070
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution
Study: NCT05330286
Drug: LMI070
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution
Study: NCT05330286
Drug: LMI070
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution given in fasted state
Study: NCT05330286
Drug: LMI070
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution given in fed state
Study: NCT06354439
Drug: Methotrexate Sodium
Normalized name: Methotrexate Sodium
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg of methotrexate IM, single dose
Study: NCT04674761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical in appearance to experimental drug (odevixibat).
Study: NCT06354088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will ingest one dose of placebo (2 overencapuslated doses of microcrystalline cellulose) on one of two study admissions.
Study: NCT04777175
Drug: immunity therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient receives immunotherapy
Study: NCT06595680
Drug: Medialipide 20% perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive during a 4 hours hemodialysis session a perfusion of Medialipide 20% at a rate of 0,11 g/kg/h. Medialipide will be perfused using the venous line connected to the hemodialysis machine.
Study: NCT06595680
Drug: NaCl 0,9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive during a 4 hours hemodialysis session a perfusion of NACL 0,9% with a volume corresponding to the one of Medialipide 20%. NaCl 0,9% will be perfused using the venous line connected to the hemodialysis machine.
Study: NCT00280839
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04922567
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750mg/m² iv on day1
Study: NCT04922567
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg/m² iv on day 1
Study: NCT06445062
Drug: RMC-6236
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06445062
Drug: mFOLFOX6 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06445062
Drug: mFOLFIRINOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06445062
Drug: RMC-9805
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06248749
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Iron supplement
Study: NCT04866602
Drug: Atoguanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone + Proguanil free base:125 mg: 87 mg, 4 tablets
Study: NCT06516094
Drug: Celecoxib+Pregabalin+Vitamin B fixed dose
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet of 200 mg / 150 mg / 100 mg / 50 mg / 0.50 mg + 1 capsule of placebo once a day
Study: NCT06516094
Drug: Celecoxib + Vitamin B fixed dose
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule of 200 mg + 1 tablet of 100 mg / 50 mg / 0.50 mg once a day
Study: NCT06459427
Drug: Conservative non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy, intensive care, maintaining stable blood pressure (targeting 140/90 mmHg), sedation, intracranial pressure control, arousal promotion, gastric protection, maintaining homeostasis, infection control, neurological nutrition, brain function improvement, nutritional support, general condition improvement, and other treatments are provided. For comatose patients, ensuring airway patency, administering nebulized expectorants, preventing respiratory depression, improving respiratory function, and performing tracheostomy if necessary are part of the care plan. Close monitoring of patients' conditions and proactive symptomatic treatment are prioritized. Regular follow-up cranial CT scans are scheduled to monitor intracranial conditions. Ventricular puncture drainage is considered if there is concomitant intraventricular hemorrhage or obstructive hydrocephalus (with patient consent).
Study: NCT05368012
Drug: MIDCAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided administration of the nerve block MIDCAB into mid-calf as analgesic intervention for patients.
Study: NCT03922048
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose instillation of approximately 0.17 mL/kg (total dose does not exceed 10.5 mL) of HTX-011.
Study: NCT03922048
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose to be determined from Cohort 1.
Study: NCT03922048
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose to be determined from Cohorts 1 and 2.
Study: NCT03922048
Drug: HTX-011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose to be determined from Cohort 1 Part A.
Study: NCT05921539
Drug: steroid hydrodilatation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultrasound-guided steroid hydrodilatation
Study: NCT05757544
Drug: IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Placebo will be administered
Study: NCT05679258
Drug: US-sourced DARZALEX®
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose (8 mg/kg) of US-sourced DARZALEX® via intravenous infusion.
Study: NCT05679258
Drug: CN-sourced DARZALEX®
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose (8 mg/kg) of CN-sourced DARZALEX® via intravenous infusion.
Study: NCT05679258
Drug: EU-sourced DARZALEX®
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose (8 mg/kg) of EU-sourced DARZALEX® via intravenous infusion.
Study: NCT06003270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00760032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, one capsule per day during four weeks.
Study: NCT04634253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05156034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV doses of placebo.
Study: NCT05895812
Drug: Deuremidevir Hydrobromide Tablets
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: JT001 single dose, 0.3g